Poster Sessions - AACR-NCI-EORTC
AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics:
Discovery, Biology, and Clinical Applications
aacr.org
November 14 - 18, 2005
Pennsylvania Convention Center
Philadelphia, PA
aacr.org Targets_poster_and_proffered_sessions.pdf
------------------
Panitumumab
------------------
A125
Identification of EGFr and K-RAS Somatic Gene Mutations from a Panitumumab Phase 2 NSCLC Clinical Trial:
Association of Mutations,Preclinical Characterization, and Clinical Outcome.
Todd Juan, DanFreeman, Ildiko Sarosi, Jeffrey Crawford, Alan Sandler, Joan Schiller,Diane Prager, David Johnson, Michael Wolf, Robert Radinsky.
B43
Panitumumab Induces Internalization of the Epidermal Growth
Factor Receptor (EGFr).
Ian N. Foltz, Chadwick T. King, Meina Liang,
Kenneth A. Schooley, Douglas P. Cerretti, Dan Freeman, Robert
Radinsky, Xiao-Dong Yang.
B64
Activity of Panitumumab Alone and in combination with
Chemotherapy Against Mutant Epidermal Growth Factor Receptor
(EGFr)- Expressing Non-small Cell Lung Carcinoma (NSCLC) Cell Lines and Xenografts.
Tammy Bush*, Dan Freeman*, Selam Ogbagabriel,
Brian Belmontes, Carl Kozlosky, Angelo Baher, Carol Johnson, Gwyneth Van, Doug Cerretti, Robert Radinsky.
B72
Antitumor Efficacy of Panitumumab Alone or in Combination with
Chemotherapy against Human Pancreatic Carcinoma Xenografts.
Tammy Bush, Dan Freeman, Selam Ogbagabriel, Beth Ziegler, Brian Belmontes, Gwyneth Van, Carol Johnson, Robert Radinsky.
B73
Antitumor Activity of AMG 706, A Novel Tyrosine Kinase Inhibitor,in Combination with Panitumumab, A Fully Human Antibody Targeting the EGF Receptor, Against Multiple Established Human Tumor Xenograft Models in Nude Mice.
C Starnes, D Freeman, T Bush,J Leal, K McDorman, A Coxon, V Patel, T Polverino, R Kendall, R Radinsky.
------------------
Erbitux®
------------------
A103
Increased Anti-tumor Efficacy of Cetuximab (Erbitux®) with
Chemotherapy in Human Non-small Cell Lung Cancer (NSCLC)
Xenografts Harboring Mutations in the Epidermal Growth Factor
Receptor (EGFR).
Philipp Steiner, Christopher Joynes, Francine Carrick,
Bridget Finnerty, Erik Corcoran, Chris Damoci, Jessica Kearney, Robin Rolser, Cindy Wang, Jacqueline Doody, Yaron Hadari, James R. Tonra, Daniel J. Hicklin.
A107
Combined Anti-EGFR Blockade:
A Phase I Pharmacokinetic and Molecular Pharmacodynamic Study of Cetuximab (Erbitux®) and Gefitinib (Iressa®) in Patients with Advanced Colorectal, Head and Neck and Non-Small Cell Lung Cancer Expressing the EGFR.
Josep Tabernero, Patrick Schöffski, Fredi Rojo, Ernst de Bruijn, Francisco J. Ramos, Herlinde Dumez, Teresa Macarulla, Hans Prenen, Esther Casado, Gunther Guetens, Vicenç Peralta, José Jiménez, Josep M. del Campo, Neus Gascon, Rosana Cajal, Erika Martinelli, Enric Jiménez,
A127
Effect of Erbitux, Erlotinib, Gefitinib and Rapamicine on the
Inhibition of EGFR Dimer Formation and Downstream Signaling
Pathways in Different Cancer Cell Lines.
Hossein Salimi-Moosavi,Xueguang Jin, Youssouf Badal, Ali Mukherjee, Hasan Tahir, Sharat Singh.
B68
Cetuximab (ERBITUX®) Enhances Clinical Efficacy of Oxaliplatin in Human Colon Carcinoma Xenografts and Reverses Oxaliplatin Resistance.
Marie Prewett, Rajiv Bassi, Francine Carrick, Bridget
Finnerty, Lee M. Ellis, Larry Witte, James R. Tonra, Daniel J. Hicklin, Fan Fan.
Don't know for certain if the above
is COMPLETE. |
